NCT07375238 Effect of Daily Intake of Gazpacho on Semen Quality and Oxidative Stress
| NCT ID | NCT07375238 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ginefiv |
| Condition | Male Infertility |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-03-02 |
| Primary Completion | 2028-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-03-02 with a primary completion date of 2028-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn whether drinking a daily serving of gazpacho can improve semen quality in men with reduced sperm quality. The study will also examine how this dietary intervention affects oxidative stress and whether it is well tolerated. The main questions this study aims to answer are: * Does daily consumption of gazpacho improve semen quality in men with altered semen parameters? * Does this dietary intervention affect levels of oxidative stress in semen? * Is daily gazpacho intake feasible and well tolerated as part of a Mediterranean diet? Researchers will compare a Mediterranean diet plus daily gazpacho intake with a Mediterranean diet alone to determine whether adding gazpacho provides additional benefits for male reproductive health. Participants will: * Follow a standardized Mediterranean diet for 12 weeks * Drink 330 mL of gazpacho every day or follow the diet without gazpacho * Provide semen samples at the start of the study and after 12 weeks * Complete a short diary to record adherence to the dietary intervention * Be followed for up to 18 months to record reproductive outcomes
Eligibility Criteria
Inclusion Criteria: * Men aged 18 to 45 years * Andrological profile including altered semen parameters such as oligozoospermia, asthenozoospermia and/or teratozoospermia (O±A±T) * No clinical indication for sperm DNA fragmentation testing or advanced sperm selection techniques * Willingness and ability to comply with the study protocol, including adherence to a standardized Mediterranean diet * Signed and dated written informed consent form Exclusion Criteria: * Use of antioxidant supplements during the three months prior to study start. * Active smokers or men who have stopped smoking within the last three months. * Diagnosis of azoospermia, leucocytospermia or necrozoospermia. * Presence of severe systemic diseases or chronic conditions that could interfere with semen quality or adherence to the study. * Known allergy or intolerance to any ingredient of the gazpacho used in the study. * Any medical, psychological or social condition that, in the investigator's judgement, could compromise the subject's ability to participate fully or comply with the protocol requirements. * Simultaneous participation in another clinical study.
Contact & Investigator
Pablo Martí Pastor, RD, RND
PRINCIPAL INVESTIGATOR
Ginefiv Madrid (IVIRMA Group)
Frequently Asked Questions
Who can join the NCT07375238 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 45 Years, studying Male Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07375238 currently recruiting?
Yes, NCT07375238 is actively recruiting participants. Contact the research team at pablo.marti@ginefiv.com for enrollment information.
Where is the NCT07375238 trial being conducted?
This trial is being conducted at Madrid, Spain.
Who is sponsoring the NCT07375238 clinical trial?
NCT07375238 is sponsored by Ginefiv. The principal investigator is Pablo Martí Pastor, RD, RND at Ginefiv Madrid (IVIRMA Group). The trial plans to enroll 80 participants.